HOME
市場調査レポート
抗ウイルス薬の世界市場2020-2027年：クラス別、用途別予測
Antiviral Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Application (HIV, Hepatitis, Influenza), By Type (Branded, Generic), By Region, And Segment Forecasts, 2020 - 2027
- 出版元：Grand View Research
出版元について - 発行年：2020年2月
- 定価 Single User License(1名様ライセンス)US$5,950(米国ドル)/Multi User License(5名様)$6,950 /Enterprise License $8,950
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文 80ページになります。
- 商品コード：GRAN115
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
抗ウイルス薬の世界市場規模は2019年で564億ドル、2027年では469億ドルとレポートでは推計しています。レポートには、新型コロナウイルス治療薬市場は対象に含まれておりません。当レポートでは、2027年に至る抗ウイルス薬の世界市場予測(市場規模US$)、クラス別市場（DNAポリメラーゼ阻害剤、逆転写酵素阻害剤、プロテアーゼ阻害剤、ノイラミニダーゼ阻害剤、その他）、タイプ別市場（ブランド、ジェネリック）、用途別市場（HIV、肺炎、ヘルペス、インフルエンザ、その他）、主要国地域別市場など、詳細な市場予測データと分析を掲載しています。また市場分析、競合状況、主要メーカー企業10社プロフィール動向などの情報も交えて、抗ウイルス薬市場の現在と今後展開を予測分析していきます。
【レポート構成概要】 
◆抗ウイルス薬の世界市場予測2016-2027年
・市場規模(US$)
◆クラス別、市場-2027年
・DNAポリメラーゼ阻害剤
・逆転写酵素阻害剤
・プロテアーゼ阻害剤
・ノイラミニダーゼ阻害剤
・その他
※(市場規模US$)
◆タイプ別、市場-2027年
・ブランド
・ジェネリック
※(市場規模US$)
◆用途別、市場-2027年
・HIV
・肺炎
・ヘルペス
・インフルエンザ
・その他
※(市場規模US$)
◆主要国地域別市場-2027年
北米
・米国、カナダ
欧州
・ドイツ、フランス、英国
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・韓国、オーストラリア
中南米
・ブラジル、メキシコ、アルゼンチン、コロンビア
中東アフリカ
・南アフリカ、サウジアラビア、UAE
※国地域別に全セグメントの細分化データ掲載、詳細は目次参照
◆市場分析
・市場ダイナミクス分析（ドライバー、障壁）
・業界動向
・PESTEL分析
・競合状況
◆抗ウイルス薬の主要企業プロフィール動向
・GILEAD SCIENCES
・F. HOFFMANN-LA ROCHE AG
・GLAXOSMITHKLINE PLC.
・ABBVIE
・MERCK & CO., INC.
・JOHNSON & JOHNSON SERVICES, INC.
・BRISTOL-MYERS SQUIBB COMPANY
・CIPLA INC.
・AUROBINDO PHARMA
・Dr. REDDY’S LABORATORIES LTD.
（全80頁）
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
英文詳細目次(table of contents)
【原文詳細目次】
Antiviral Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Application (HIV, Hepatitis, Influenza), By Type (Branded, Generic), By Region, And Segment Forecasts, 2020 - 2027
Table of Contents
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. MARKET SEGMENTATION & SCOPE
1.2. INFORMATION PROCUREMENT
1.2.1. PURCHASED DATABASE
1.2.2. GVR’S INTERNAL DATABASE
1.2.3. SECONDARY SOURCES & THIRD-PARTY PERSPECTIVES
1.2.4. PRIMARY RESEARCH
1.3. INFORMATION ANALYSIS
1.3.1. DATA ANALYSIS MODELS
1.4. MARKET FORMULATION & DATA VISUALIZATION
1.5. DATA VALIDATION & PUBLISHING
CHAPTER 2. EXECUTIVE SUMMARY
2.1. MARKET OUTLOOK
2.2. SEGMENT OUTLOOK
2.3. COMPETITIVE INSIGHTS
CHAPTER 3. ANTIVIRAL DRUGS MARKET VARIABLES, TRENDS & SCOPE
3.1. MARKET LINEAGE OUTLOOK
3.1.1. PARENT/ ANCILLARY MARKET OUTLOOK
3.2. PENETRATION & GROWTH PROSPECT MAPPING
3.3. PIPELINE ANALYSIS
3.4. MARKET DYNAMICS
3.4.1. MARKET DRIVER ANALYSIS
3.4.1.1. INCREASING PREVALENCE OF VIRAL INFECTIONS SUCH AS HEPATITIS AND HIV
3.4.1.2. PRESENCE OF PIPELINE PRODUCTS FOR HIV TREATMENT
3.4.1.3. INCREASING GERIATRIC POPULATION
3.4.2. MARKET RESTRAINT ANALYSIS
3.4.2.1. PRESENCE OF GENERICS
3.4.2.2. RISING AWARENESS AND PREVENTIVE TREATMENTS
3.5. ANTIVIRAL DRUGS: MARKET ANALYSIS TOOLS
3.5.1. INDUSTRY ANALYSIS - PORTER’S
3.5.1.1. SUPPLIER POWER
3.5.1.2. BUYER POWER
3.5.1.3. SUBSTITUTION THREAT
3.5.1.4. THREAT FROM NEW ENTRANT
3.5.1.5. COMPETITIVE RIVALRY
3.5.2. PESTEL ANALYSIS
3.5.2.1. POLITICAL LANDSCAPE
3.5.2.2. ENVIRONMENTAL LANDSCAPE
3.5.2.3. SOCIAL LANDSCAPE
3.5.2.4. TECHNOLOGY LANDSCAPE
3.5.2.5. LEGAL LANDSCAPE
CHAPTER 4. ANTIVIRAL DRUGS MARKET: SEGMENT ANALYSIS, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
4.1. DEFINITIONS & SCOPE
4.2. DRUG CLASS MARKET SHARE ANALYSIS, 2019 & 2027
4.3. SEGMENT DASHBOARD
4.4. GLOBAL ANTIVIRAL DRUGS MARKET, BY DRUGS CLASS, 2016 TO 2027
4.5. MARKET SIZE & FORECASTS AND TREND ANALYSES, 2016 TO 2027 FOR THE FOLLOWING
4.5.1. DNA POLYMERASE INHIBITORS
4.5.2. REVERSE TRANSCRIPTASE INHIBITORS
4.5.3. PROTEASE INHIBITORS
4.5.4. NEURAMINIDASE INHIBITORS
4.5.5. OTHERS
CHAPTER 5. ANTIVIRAL DRUGS MARKET: SEGMENT ANALYSIS, BY TYPE, 2016 - 2027 (USD BILLION)
5.1. DEFINITIONS & SCOPE
5.2. TYPE MARKET SHARE ANALYSIS, 2019 & 2027
5.3. SEGMENT DASHBOARD
5.4. GLOBAL ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 TO 2027
5.5. MARKET SIZE & FORECASTS AND TREND ANALYSES, 2016 TO 2027 FOR THE FOLLOWING
5.5.1. BRANDED
5.5.2. GENERICS
CHAPTER 6. ANTIVIRAL DRUGS MARKET: SEGMENT ANALYSIS, BY APPLICATION, 2016 - 2027 (USD BILLION)
6.1. DEFINITIONS & SCOPE
6.2. APPLICATION MARKET SHARE ANALYSIS, 2019 & 2027
6.3. SEGMENT DASHBOARD
6.4. GLOBAL ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 TO 2027
6.5. MARKET SIZE & FORECASTS AND TREND ANALYSES, 2016 TO 2027 FOR THE FOLLOWING
6.5.1. HIV
6.5.2. HEPATITIS
6.5.3. HERPES
6.5.4. INFLUENZA
6.5.5. OTHERS
CHAPTER 7. ANTIVIRAL DRUGS MARKET: REGIONAL MARKET ANALYSIS, BY REGION, 2016 - 2027 (USD BILLION)
7.1. DEFINITIONS & SCOPE
7.2. REGIONAL MARKET SHARE ANALYSIS, 2019 & 2027
7.3. REGIONAL MARKET DASHBOARD
7.4. REGIONAL MARKET SHARE AND LEADING PLAYERS, 2019
7.5. SWOT ANALYSIS, BY FACTOR (POLITICAL & LEGAL, ECONOMIC AND TECHNOLOGICAL)
7.5.1. NORTH AMERICA
7.5.2. EUROPE
7.5.3. ASIA PACIFIC
7.5.4. LATIN AMERICA
7.5.5. MIDDLE EAST & AFRICA
7.6. MARKET SIZE, & FORECASTS AND TREND ANALYSIS, 2019 TO 2027
7.7. NORTH AMERICA
7.7.1 MARKET ESTIMATES AND FORECAST, BY COUNTRY, 2016 - 2027 (USD BILLION)
7.7.2 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.7.3 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.7.4 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.7.5 U.S.
7.7.5.1 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.7.5.2 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.7.5.3 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.7.6 CANADA
7.7.6.1 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.7.6.2 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.7.6.3 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.8. EUROPE
7.8.1 MARKET ESTIMATES AND FORECAST, BY COUNTRY, 2016 - 2027 (USD BILLION)
7.8.2 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.8.3 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.8.4 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.8.5 GERMANY
7.8.5.1 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.8.5.2 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.8.5.3 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.8.6 U.K.
7.8.6.1 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.8.6.2 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.8.6.3 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.8.7 FRANCE
7.8.7.1 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.8.7.2 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.8.7.3 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.8.8 ITALY
7.8.8.1 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.8.8.2 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.8.8.3 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.8.9 SPAIN
7.8.9.1 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.8.9.2 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.8.9.3 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.9 ASIA PACIFIC
7.9.1 MARKET ESTIMATES AND FORECAST, BY COUNTRY, 2016 - 2027 (USD BILLION)
7.9.2 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.9.3 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.9.4 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.9.5 CHINA
7.9.5.1 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.9.5.2 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.9.5.3 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.9.6 JAPAN
7.9.6.1 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.9.6.2 MARKET ESTIMATES AND FORECAST, BY TYPE2016 - 2027 (USD BILLION)
7.9.6.3 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.9.7 INDIA
7.9.7.1 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.9.7.2 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.9.7.3 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.9.8 AUSTRALIA
7.9.8.1 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.9.8.2 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.9.8.3 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.9.9 SOUTH KOREA
7.9.9.1 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.9.9.2 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.9.9.3 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.10 LATIN AMERICA
7.10.1 MARKET ESTIMATES AND FORECAST, BY COUNTRY, 2016 - 2027 (USD BILLION)
7.10.2 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.10.3 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.10.4 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.10.5 BRAZIL
7.10.5.1 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.10.5.2 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.10.5.3 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.10.6 MEXICO
7.10.6.1 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.10.6.2 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.10.6.3 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.10.7 ARGENTINA
7.10.7.1 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.10.7.2 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.10.7.3 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.10.8 COLOMBIA
7.10.8.1 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.10.8.2 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.10.8.3 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.11 MIDDLE EAST AND AFRICA
7.11.1 MARKET ESTIMATES AND FORECAST, BY COUNTRY, 2016 - 2027 (USD BILLION)
7.11.2 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.11.3 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.11.4 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.11.5 SOUTH AFRICA
7.11.5.1 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.11.5.2 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.11.5.3 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.11.6 SAUDI ARABIA
7.11.6.1 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.11.6.2 MARKET ESTIMATES AND FORECAST, BY TYPE2016 - 2027 (USD BILLION)
7.11.6.3 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
7.11.7 UAE
7.11.7.1 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
7.11.7.2 MARKET ESTIMATES AND FORECAST, BY TYPE, 2016 - 2027 (USD BILLION)
7.11.7.3 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2016 - 2027 (USD BILLION)
CHAPTER 8. ANTIVIRAL DRUGS MARKET - COMPETITIVE ANALYSIS
8.1. RECENT DEVELOPMENTS & IMPACT ANALYSIS, BY KEY MARKET PARTICIPANTS
8.2. COMPANY/COMPETITION CATEGORIZATION (KEY INNOVATORS, MARKET LEADERS, EMERGING PLAYERS)
8.3. PUBLIC COMPANIES
8.3.1. COMPANY MARKET POSITION ANALYSIS (REVENUE, GEOGRAPHIC PRESENCE, PRODUCT PORTFOLIO, KEY SERVICEABLE INDUSTRIES, KEY ALLIANCES)
8.3.2. COMPANY MARKET SHARE/RANKING, BY REGION
8.3.3. COMPETITIVE DASHBOARD ANALYSIS
8.4. PRIVATE COMPANIES
8.4.1. LIST OF KEY EMERGING COMPANIES/TECHNOLOGY DISRUPTORS/INNOVATORS
8.4.2. REGIONAL NETWORK MAP
8.4.3. COMPANY MARKET POSITION ANALYSIS
8.5. KEY COMPANIES PROFILED
8.5.1. GILEAD SCIENCES
8.5.1.1. COMPANY OVERVIEW
8.5.1.2. FINANCIAL PERFORMANCE
8.5.1.3. PRODUCT BENCHMARKING
8.5.1.4. STRATEGIC INITIATIVES
8.5.2. F. HOFFMANN-LA ROCHE AG
8.5.2.1. COMPANY OVERVIEW
8.5.2.2. FINANCIAL PERFORMANCE
8.5.2.3. PRODUCT BENCHMARKING
8.5.2.4. STRATEGIC INITIATIVES
8.5.3. GLAXOSMITHKLINE PLC.
8.5.3.1. COMPANY OVERVIEW
8.5.3.2. FINANCIAL PERFORMANCE
8.5.3.3. PRODUCT BENCHMARKING
8.5.3.4. STRATEGIC INITIATIVES
8.5.4. ABBVIE
8.5.4.1. COMPANY OVERVIEW
8.5.4.2. FINANCIAL PERFORMANCE
8.5.4.3. PRODUCT BENCHMARKING
8.5.4.4. STRATEGIC INITIATIVES
8.5.5. MERCK & CO., INC.
8.5.5.1. COMPANY OVERVIEW
8.5.5.2. FINANCIAL PERFORMANCE
8.5.5.3. PRODUCT BENCHMARKING
8.5.5.4. STRATEGIC INITIATIVES
8.5.6. JOHNSON & JOHNSON SERVICES, INC.
8.5.6.1. COMPANY OVERVIEW
8.5.6.2. FINANCIAL PERFORMANCE
8.5.6.3. PRODUCT BENCHMARKING
8.5.6.4. STRATEGIC INITIATIVES
8.5.7. BRISTOL-MYERS SQUIBB COMPANY
8.5.7.1. COMPANY OVERVIEW
8.5.7.2. FINANCIAL PERFORMANCE
8.5.7.3. PRODUCT BENCHMARKING
8.5.7.4. STRATEGIC INITIATIVES
8.5.8. CIPLA INC.
8.5.8.1. COMPANY OVERVIEW
8.5.8.2. FINANCIAL PERFORMANCE
8.5.8.3. PRODUCT BENCHMARKING
8.5.8.4. STRATEGIC INITIATIVES
8.5.9. AUROBINDO PHARMA
8.5.9.1. COMPANY OVERVIEW
8.5.9.2. FINANCIAL PERFORMANCE
8.5.9.3. PRODUCT BENCHMARKING
8.5.9.4. STRATEGIC INITIATIVES
8.5.10. DR. REDDY’S LABORATORIES LTD.
8.5.10.1. COMPANY OVERVIEW
8.5.10.2. FINANCIAL PERFORMANCE
8.5.10.3. PRODUCT BENCHMARKING
8.5.10.4. STRATEGIC INITIATIVES
LIST OF TABLES
TABLE 1 LIST OF ABBREVIATIONS
TABLE 2 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 3 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 4 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 5 U.S. ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 6 U.S. ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 7 U.S. ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 8 CANADA ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 9 CANADA ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 10 CANADA ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 11 EUROPE ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 12 EUROPE ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 13 EUROPE ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 14 GERMANY ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 15 GERMANY ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 16 GERMANY ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 17 U.K. ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 18 U.K. ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 19 U.K. ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 20 ITALY ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 21 ITALY ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 22 ITALY ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 23 FRANCE ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 24 FRANCE ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 25 FRANCE ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 26 SPAIN ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 27 SPAIN ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 28 SPAIN ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 29 ASIA PACIFIC ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 30 ASIA PACIFIC ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 31 ASIA PACIFIC ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 32 JAPAN ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 33 JAPAN ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 34 JAPAN ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 35 CHINA ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 36 CHINA ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 37 CHINA ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 38 INDIA ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 39 INDIA ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 40 INDIA ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 41 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 42 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 43 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 44 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 45 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 46 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 47 LATIN AMERICA ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 48 LATIN AMERICA ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 49 LATIN AMERICA ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 50 BRAZIL ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 51 BRAZIL ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 52 BRAZIL ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 53 MEXICO ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 54 MEXICO ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 55 MEXICO ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 56 ARGENTINA ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 57 ARGENTINA ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 58 ARGENTINA ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 59 COLOMBIA ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 60 COLOMBIA ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 61 COLOMBIA ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 62 MEA ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 63 MEA ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 64 MEA ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 65 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 66 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 67 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 68 UAE ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 69 UAE ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 70 UAE ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
TABLE 71 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY DRUG CLASS, 2016 - 2027 (USD BILLION)
TABLE 72 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY TYPE, 2016 - 2027 (USD BILLION)
TABLE 73 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY APPLICATION, 2016 - 2027 (USD BILLION)
LIST OF FIGURES
FIG. 1 MARKET RESEARCH PROCESS
FIG. 2 INFORMATION PROCUREMENT
FIG. 3 MARKET SUMMARY
FIG. 4 MARKET SEGMENTATION & SCOPE
FIG. 5 MARKET SIZE AND GROWTH PROSPECTS
FIG. 6 GLOBAL ANTIVIRAL DRUGS MARKET - KEY MARKET DRIVER ANALYSIS
FIG. 7 GLOBAL ANTIVIRAL DRUGS MARKET - KEY MARKET RESTRAINT ANALYSIS
FIG. 8 PENETRATION & GROWTH PROSPECT MAPPING
FIG. 9 GLOBAL ANTIVIRAL DRUGS MARKET - PORTER’S ANALYSIS
FIG. 10 GLOBAL ANTIVIRAL DRUGS MARKET - PESTEL ANALYSIS
FIG. 11 GLOBAL ANTIVIRAL DRUGS MARKET DRUG CLASS OUTLOOK KEY TAKEAWAYS
FIG. 12 GLOBAL ANTIVIRAL DRUGS MARKET: DRUG CLASS MOVEMENT ANALYSIS
FIG. 13 DNA POLYMERASE INHIBITORS MARKET ESTIMATES, 2016 - 2027 (USD BILLION)
FIG. 14 REVERSE TRANSCRIPTASE INHIBITORS MARKET ESTIMATES, 2016 - 2027 (USD BILLION)
FIG. 15 PROTEASE INHIBITORS MARKET ESTIMATES, 2016 - 2027 (USD BILLION)
FIG. 16 NEURAMINIDASE INHIBITORS MARKET ESTIMATES, 2016 - 2027 (USD BILLION)
FIG. 17 OTHERS MARKET ESTIMATES, 2016 - 2027 (USD BILLION)
FIG. 18 GLOBAL ANTIVIRAL DRUGS MARKET TYPE OUTLOOK KEY TAKEAWAYS
FIG. 19 GLOBAL ANTIVIRAL DRUGS MARKET: TYPE MOVEMENT ANALYSIS
FIG. 20 BRANDED MARKET ESTIMATES, 2016 - 2027 (USD BILLION)
FIG. 21 GENERICS MARKET ESTIMATES, 2016 - 2027 (USD BILLION)
FIG. 22 GLOBAL ANTIVIRAL DRUGS MARKET APPLICATION OUTLOOK KEY TAKEAWAYS
FIG. 23 GLOBAL ANTIVIRAL DRUGS MARKET: APPLICATION MOVEMENT ANALYSIS
FIG. 24 HIV MARKET ESTIMATES, 2016 - 2027 (USD BILLION)
FIG. 25 HEPATITIS MARKET ESTIMATES, 2016 - 2027 (USD BILLION)
FIG. 26 HERPES MARKET ESTIMATES, 2016 - 2027 (USD BILLION)
FIG. 27 INFLUENZA MARKET ESTIMATES, 2016 - 2027 (USD BILLION)
FIG. 28 OTHERS MARKET ESTIMATES, 2016 - 2027 (USD BILLION)
FIG. 29 REGIONAL MARKETPLACE: KEY TAKEAWAYS
FIG. 30 GLOBAL ANTIVIRAL DRUGS MARKET: REGIONAL MOVEMENT ANALYSIS
FIG. 31 NORTH AMERICA ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 32 U.S. ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 33 CANADA ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 34 EUROPE ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 35 U.K. ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 36 GERMANY ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 37 FRANCE ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 38 SPAIN ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 39 ITALY ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 40 ASIA PACIFIC ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 41 JAPAN ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 42 CHINA ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 43 INDIA ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 44 SOUTH KOREA ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 45 AUSTRALIA ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 46 LATIN AMERICA ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG 47 BRAZIL ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 48 MEXICO ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 49 ARGENTINA ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 50 COLOMBIA ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 51 MEA ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 52 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 53 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, 2016 - 2027 (USD BILLION)
FIG. 54 UAE MARKET, 2016 - 2027 (USD BILLION)
FIG. 55 STRATEGY FRAMEWORK
掲載企業リスト
プレスリリース
プレスリリース
当レポートのプレスリリースは発行されておりません。
リサーチカテゴリ一覧
スマートグリッド
お問合わせはこちらから
